Gianni Chessari,Ian R. Hardcastle,Jong Sook Ahn,Burcu Anil,Elizabeth Anscombe,Ruth H. Bawn,Luke D. Bevan,Timothy J. Blackburn,Ildiko Buck,Celine Cano,Benoit Carbain,Juan Castro,Ben Cons,Sarah J. Cully,Jane A. Endicott,Lynsey Fazal,Bernard T. Golding,Roger J. Griffin,Karen Haggerty,Suzannah J. Harnor,Keisha Hearn,Stephen Hobson,Rhian S. Holvey,Steven Howard,Claire E. Jennings,Christopher N. Johnson,John Lunec,Duncan C. Miller,David R. Newell,Martin E. M. Noble,Judith Reeks,Charlotte H. Revill,Christiane Riedinger,Jeffrey D. St. Denis,Emiliano Tamanini,Huw Thomas,Neil T. Thompson,Mladen Vinković,Stephen R. Wedge,Pamela A. Williams,Nicola E. Wilsher,Bian Zhang,Yan Zhao,Mladen Vinković

Abstract:Inhibition of murine double minute 2 (MDM2)-p53 protein–protein interaction with small molecules has been shown to reactivate p53 and inhibit tumor growth. Here, we describe rational, structure-guided, design of novel isoindolinone-based MDM2 inhibitors. MDM2 X-ray crystallography, quantum mechanics ligand-based design, and metabolite identification all contributed toward the discovery of potent in vitro and in vivo inhibitors of the MDM2-p53 interaction with representative compounds inducing cytostasis in an SJSA-1 osteosarcoma xenograft model following once-daily oral administration.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02188?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02188</a>.Molecular formula string (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_001.csv">CSV</a>)Model of the X-ray crystal structure of MDM2 with compound 4 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_002.cif">CIF</a>)Structure factors of the X-ray crystal structure of MDM2 with compound 4 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_003.cif">CIF</a>)Additional experimental details for compounds not included in the main section and analytical data for all compounds and intermediates; NMR studies on 5; X-ray structure tables; and computational chemistry (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_004.pdf">PDF</a>)This article has not yet been cited by other publications.

Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the Mdm2-P53 Interaction

Optimization Beyond Amg 232: Discovery and Sar of Sulfonamides on A Piperidinone Scaffold As Potent Inhibitors of the Mdm2-P53 Protein-Protein Interaction

Discovery of Novel 3,3-Disubstituted Piperidines As Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.

Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.

Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives As Novel Inhibitors of P53-Mdm2 Protein-Protein Interaction.

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction

Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy.

Small Molecule Inhibitors of the P53-Mdm2

Design, Synthesis and Biological Evaluation of Novel Antitumor Spirotetrahydrothiopyran-Oxindole Derivatives As Potent P53-Mdm2 Inhibitors

Synthesis and biological evaluation of 4-imidazolidinone–containing compounds as potent inhibitors of the MDM2/p53 interaction

Discovery of Quinazoline-2,4(1 H,3 H)-dione Derivatives Containing a Piperizinone Moiety as Potent PARP-1/2 Inhibitors─Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis

Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum IV Complexes as Potent Antitumor Agents

Design, synthesis and biological evaluation of sulfamide and triazole benzodiazepines as novel p53-MDM2 inhibitors.

Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors

Discovery of (R)-5-((5-(1-methyl-1h-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a Novel CHK1 Inhibitor for Hematologic Malignancies.

Small Molecules Simultaneously Inhibiting P53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (hdacs): Discovery of Novel Multitargeting Antitumor Agents

Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.

Design, Synthesis and Structure–activity Relationship of 4,5-Dihydropyrrolo[3,4-c]pyrazol-6(1h)-ones As Potent P53-Mdm2 Inhibitors

Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein-Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy

Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53

Design, Synthesis, and Biological Evaluation of Pyrido[2,3-d]pyrimidin-7(8H)-one Derivatives As Potent USP1 Inhibitors